Related Experiment Video

Updated: Jun 21, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Pediatric TB: issues related to current and future treatment options

Ben J Marais1, H Simon Schaaf, Peter R Donald

  • 1Department of Paediatrics & Child Health, Faculty of Health Sciences, Stellenbosch University, Tygerberg, 7505, South Africa. bjmarais@sun.ac.za

Future Microbiology
|August 8, 2009
PubMed

Insights

Pediatric tuberculosis (TB) remains neglected in low-resource areas. Despite improved drug access and guidelines, diagnosing and treating children effectively faces significant programmatic challenges.

Area of Science:

  • Global Health
  • Infectious Diseases
  • Pediatrics

Background:

  • Pediatric tuberculosis (TB) is a significant global health concern, disproportionately affecting children in endemic regions.
  • Limited resources in these areas often prioritize treatment for the most infectious TB cases, neglecting children.
  • Growing recognition of children's substantial TB burden, morbidity, and mortality highlights the need for focused interventions.

Purpose of the Study:

  • To provide an overview of current pediatric TB treatment practices in endemic areas.
  • To identify factors influencing effective TB therapy delivery to children.
  • To discuss potential future advances and authors' perspectives on pediatric TB management.

Main Methods:

  • Literature review summarizing relevant research on pediatric TB.
  • Analysis of programmatic barriers and diagnostic challenges in resource-limited settings.
  • Inclusion of expert perspectives on current and future pediatric TB treatment.

Main Results:

  • WHO guidelines and child-friendly drug formulations have been available since 2006 and 2008, respectively.
  • Significant programmatic barriers and diagnostic difficulties persist in resource-limited settings.
  • Effective treatment for pediatric TB requires addressing these multifaceted challenges.

Conclusions:

  • Pediatric TB requires increased attention and tailored strategies for diagnosis and treatment in endemic regions.
  • Overcoming programmatic and resource limitations is crucial for improving outcomes for children with TB.
  • Continued research and collaborative efforts are essential for advancing pediatric TB care globally.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...